| Chronic graft-versus-host disease
Jakafi vs Niktimvo
Side-by-side clinical, coverage, and cost comparison for chronic graft-versus-host disease.Deep comparison between: Jakafi vs Niktimvo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNiktimvo has a higher rate of injection site reactions vs Jakafi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Niktimvo but not Jakafi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jakafi
Niktimvo
At A Glance
Oral
Twice daily
JAK1/JAK2 inhibitor
IV infusion
Every 2 weeks
CSF-1R antagonist
Indications
- Myelofibrosis
- Polycythemia Vera
- Acute GVH disease
- Chronic graft-versus-host disease
- Chronic graft-versus-host disease
Dosing
Myelofibrosis Starting dose based on platelet count: 20 mg orally twice daily (>200 x 10^9/L), 15 mg twice daily (100-200 x 10^9/L), or 5 mg twice daily (50 to <100 x 10^9/L); doses may be titrated up to 25 mg twice daily based on safety and efficacy.
Polycythemia Vera 10 mg orally twice daily starting dose; doses may be titrated up to 25 mg twice daily based on safety and efficacy.
Acute GVH disease 5 mg orally twice daily starting dose; may increase to 10 mg twice daily after at least 3 days if ANC and platelet counts are not decreased by 50% or more relative to the first day of dosing.
Chronic graft-versus-host disease 10 mg orally twice daily starting dose; taper after 6 months in patients with response who have discontinued therapeutic doses of corticosteroids.
Chronic graft-versus-host disease 0.3 mg/kg (maximum 35 mg) as an intravenous infusion over 30 minutes every 2 weeks until progression or unacceptable toxicity; for patients weighing at least 40 kg.
Contraindications
—
—
Adverse Reactions
Most common Thrombocytopenia, anemia, neutropenia, bruising, dizziness, headache, infections, edema, hemorrhage, fatigue
Serious Thrombocytopenia, anemia, neutropenia, infections, non-melanoma skin cancer, major adverse cardiovascular events, thrombosis, secondary malignancies
Postmarketing Herpes simplex virus reactivation and/or dissemination
Most common (>=15%) Increased AST, infection (pathogen unspecified), increased ALT, decreased phosphate, decreased hemoglobin, viral infection, increased GGT, musculoskeletal pain, increased lipase, fatigue, increased amylase, increased calcium, increased CPK, increased ALP, nausea, headache, diarrhea, cough, bacterial infection, pyrexia, dyspnea
Serious Infection (pathogen unspecified), viral infection, respiratory failure
Pharmacology
Ruxolitinib is a kinase inhibitor that selectively inhibits JAK1 and JAK2, which mediate cytokine and growth factor signaling important for hematopoiesis and immune function; dysregulated JAK1/JAK2 signaling underlies myelofibrosis, polycythemia vera, and GVHD pathogenesis.
Axatilimab-csfr is a CSF-1R antagonist; a monoclonal antibody that binds to colony stimulating factor-1 receptors (CSF-1R) on monocytes and macrophages, reducing circulating proinflammatory and profibrotic monocytes and monocyte-derived macrophages, and inhibiting the activity of pathogenic macrophages in tissues.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jakafi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (10/12) · Qty limit (11/12)
Niktimvo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Jakafi
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (7/8)
Niktimvo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Jakafi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Niktimvo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Jakafi.
$15/fillfill
IncyteCARES for Niktimvo Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JakafiView full Jakafi profile
NiktimvoView full Niktimvo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.